Single Biggest Cancer Dictionary in the World
What is KRASG12C inhibitor JNJ-74699157?
Pronunciation: /krasg* twɛlv si ˌɪnˈhɪbətər jnj* seventy-four* ˈmɪljən, sɪks ˈhənərd ənd ninety-nine* ˈθaʊzənd, wən ˈhənərd ənd fifty-seven*/
KRASG12C inhibitor JNJ-74699157
Definition
An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.